Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 124

1.

Toxicities associated with dual nucleoside reverse-transcriptase inhibitor regimens in HIV-infected children.

Van Dyke RB, Wang L, Williams PL; Pediatric AIDS Clinical Trials Group 219C Team..

J Infect Dis. 2008 Dec 1;198(11):1599-608. doi: 10.1086/593022.

2.

Response to zidovudine/didanosine-containing combination antiretroviral therapy among HIV-1 subtype C-infected adults in Botswana: two-year outcomes from a randomized clinical trial.

Bussmann H, Wester CW, Thomas A, Novitsky V, Okezie R, Muzenda T, Gaolathe T, Ndwapi N, Mawoko N, Widenfelt E, Moyo S, Musonda R, Mine M, Makhema J, Moffat H, Essex M, Degruttola V, Marlink RG.

J Acquir Immune Defic Syndr. 2009 May 1;51(1):37-46. doi: 10.1097/QAI.0b013e31819ff102.

3.

Nucleoside analogue mutations and Q151M in HIV-1 subtype A/E infection treated with nucleoside reverse transcriptase inhibitors.

Sirivichayakul S, Ruxrungtham K, Ungsedhapand C, Techasathit W, Ubolyam S, Chuenyam T, Emery S, Cooper D, Lange J, Phanuphak P.

AIDS. 2003 Sep 5;17(13):1889-96.

PMID:
12960821
4.

Vitamin D attenuates nucleoside reverse transcriptase inhibitor induced human skeletal muscle mitochondria DNA depletion.

Campbell GR, Pallack ZT, Spector SA.

AIDS. 2013 Jun 1;27(9):1397-401. doi: 10.1097/QAD.0b013e32836010dd.

5.

Intracellular nucleoside triphosphate concentrations in HIV-infected patients on dual nucleoside reverse transcriptase inhibitor therapy.

Moore JD, Acosta EP, Johnson VA, Bassett R, Eron JJ, Fischl MA, Long MC, Kuritzkes DR, Sommadossi JP.

Antivir Ther. 2007;12(6):981-6.

PMID:
17926654
6.

In vitro analysis of synergism and antagonism of different nucleoside/nucleotide analogue combinations on the inhibition of human immunodeficiency virus type 1 replication.

Perez-Olmeda M, Garcia-Perez J, Mateos E, Spijkers S, Ayerbe MC, Carcas A, Alcami J.

J Med Virol. 2009 Feb;81(2):211-6. doi: 10.1002/jmv.21377.

PMID:
19107982
7.

An open randomized controlled trial of zidovudine plus lamivudine versus stavudine plus lamivudine.

Foudraine NA, de Jong JJ, Jan Weverling G, van Benthem BH, Maas J, Keet IP, Jurriaans S, Roos MT, Vandermeulen K, de Wolf F, Lange JM.

AIDS. 1998 Aug 20;12(12):1513-9.

PMID:
9727573
8.

A comparison of stavudine, didanosine and indinavir with zidovudine, lamivudine and indinavir for the initial treatment of HIV-1 infected individuals: selection of thymidine analog regimen therapy (START II).

Eron JJ Jr, Murphy RL, Peterson D, Pottage J, Parenti DM, Jemsek J, Swindells S, Sepulveda G, Bellos N, Rashbaum BC, Esinhart J, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1601-10.

PMID:
10983647
10.

Long-term subcutaneous tissue changes among antiretroviral-naive persons initiating stavudine, zidovudine, or abacavir with lamivudine.

Shlay JC, Sharma S, Peng G, Gibert CL, Grunfeld C.

J Acquir Immune Defic Syndr. 2008 May 1;48(1):53-62.

PMID:
18491421
11.

Three-year durability of dual-nucleoside versus triple-nucleoside therapy in a Thai population with HIV infection.

Ungsedhapand C, Srasuebkul P, Cardiello P, Ruxrungtham K, Ratanasuwan W, Kroon ED, Tongtalung M, Juengprasert N, Ubolyam S, Siangphoe U, Emery S, Lange JM, Cooper DA, Phanuphak P; HIV-NAT 002 and HIV-NAT 003 Study Team..

J Acquir Immune Defic Syndr. 2004 Jun 1;36(2):693-701.

PMID:
15167288
12.

First-line therapy and mitochondrial damage: different nucleosides, different findings.

Blanco F, García-Benayas T, José de la Cruz J, González-Lahoz J, Soriano V.

HIV Clin Trials. 2003 Jan-Feb;4(1):11-9.

PMID:
12577192
13.

Comparison of antiviral activity of regimens containing nucleos(t)ide (NUC) Pairs in HIV-Infected Patients Initiating REScue therapy (The NUCREST Study).

Pérez-Molina JA, Serrano O, Milinkovic A, Domingo P, Currán A, Knobel H, Gaspar G, Rodrigo A, Jiménez-Expósito MJ, Hernández-Novoa B, Moreno S, The NUCREST Study.

HIV Clin Trials. 2010 Sep-Oct;11(5):294-302. doi: 10.1310/hct1105-294.

PMID:
21126959
14.

A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).

Squires KE, Gulick R, Tebas P, Santana J, Mulanovich V, Clark R, Yangco B, Marlowe SI, Wright D, Cohen C, Cooley T, Mauney J, Uffelman K, Schoellkopf N, Grosso R, Stevens M.

AIDS. 2000 Jul 28;14(11):1591-600.

PMID:
10983646
15.

Lamivudine in combination with zidovudine, stavudine, or didanosine in patients with HIV-1 infection. A randomized, double-blind, placebo-controlled trial. National Institute of Allergy and Infectious Disease AIDS Clinical Trials Group Protocol 306 Investigators.

Kuritzkes DR, Marschner I, Johnson VA, Bassett R, Eron JJ, Fischl MA, Murphy RL, Fife K, Maenza J, Rosandich ME, Bell D, Wood K, Sommadossi JP, Pettinelli C.

AIDS. 1999 Apr 16;13(6):685-94.

PMID:
10397563
17.

Transplacentally exposed human and monkey newborn infants show similar evidence of nucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity.

Divi RL, Leonard SL, Kuo MM, Nagashima K, Thamire C, St Claire MC, Wade NA, Walker VE, Poirier MC.

Environ Mol Mutagen. 2007 Apr-May;48(3-4):201-9.

PMID:
16538687
18.

Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection.

Yogev R, Lee S, Wiznia A, Nachman S, Stanley K, Pelton S, Mofenson L, Fiscus S, Jimenez E, Rathore MH, Smith ME, Song LY, McIntosh K; Pediatrics AIDS Clinical Trials Group 338 Study Team..

Pediatr Infect Dis J. 2002 Feb;21(2):119-25.

PMID:
11840078
20.

Assessment of adipokine expression and mitochondrial toxicity in HIV patients with lipoatrophy on stavudine- and zidovudine-containing regimens.

Jones SP, Qazi N, Morelese J, Lebrecht D, Sutinen J, Yki-Jărvinen H, Back DJ, Pirmohamed M, Gazzard BG, Walker UA, Moyle GJ.

J Acquir Immune Defic Syndr. 2005 Dec 15;40(5):565-72.

PMID:
16284533

Supplemental Content

Support Center